USSN: 10/611,398 Atty. Dkt. No.: PP000338.0105 2300-0338.02

## IN THE CLAIMS

This listing of the claims replaces all prior versions of the claims in the application.

- 1. (currently amended): An isolated immunogenic detoxified protein comprising the amino acid sequence of subunit A of a cholera toxin (CT-A) or the amino acid sequence of subunit A of an Escherichia coli heat labile toxin (LT-A) wherein the amino acids at positions corresponding to Ser-63 and Arg-192 of SEQ ID NO:7 or SEQ ID NO:8 are replaced with another amino acid, and further wherein the amino acid at position corresponding to Ser-63 is replaced with a lysine residue and the amino acid corresponding to position Arg-192 is replaced with a glycine or an asparagine residue.
- (previously presented): A vaccine composition comprising an immunogenic detoxified protein according to claim 1 and a pharmaceutically acceptable carrier.
- 3. (original): A vaccine composition according to claim 2 further comprising an adjuvant.
- (previously presented): A vaccine composition according to claim 2 further comprising a second immunogenic antigen.
  - 5 to 9. (canceled).
- 10. (withdrawn): A method of vaccinating a mammal against Vibrio cholerae or an entertoxigenic strain of Escherichi coli comprising administering an immunologically effective amount of an immunogenic detoxified protein according to claim 1.

USSN: 10/611.398

Atty. Dkt. No.: PP000338.0105

2300-0338.02

11. (withdrawn): A method for the prevention or treatment of disease in a subject comprising administering to the subject an immunologically effective dose of a composition according to claim 4.

- 12. (withdrawn): A process for the formulation of a vaccine comprising bringing an immunogenic detoxified protein according to claim 1 into association with a pharmaceutically acceptable carrier.
- 13. (withdrawn): The process according to claim 12, further comprising bringing the vaccine into association with an adjuvant.
- 14. (withdrawn): The process according to claim 12, further comprising bringing the vaccine into association with a second antigen.
- 15. (withdrawn): The immunogenic detoxified protein of claim 1, wherein the protein comprises the amino acid sequence of subunit A of a cholera toxin (CT-A) or a fragment thereof.
- 16. (withdrawn): The immunogenic detoxified protein of claim 15, wherein the amino acid at, or in a position corresponding to, Arg-192 is replaced with Asn-192 or Gly-192.
- 17. (withdrawn): The immunogenic detoxified protein of claim 16, wherein the amino acid at, or in a position corresponding to, Arg-192 is replaced with Asn-192.
- 18. (withdrawn): The immunogenic detoxified protein of claim 16, wherein the amino acid at, or in a position corresponding to, Arg-192 is replaced with Gly-192.

USSN: 10/611,398

Atty. Dkt. No.: PP000338.0105 2300-0338.02

19. (previously presented): The immunogenic detoxified protein of claim 1, wherein the protein comprises the amino acid sequence of subunit A of an Escherichi coli heat labile toxin (LT-A).

20 to 22. (canceled).

- 23. (previously presented): The immunogenic detoxified protein of claim 2, wherein the detoxified protein has a toxicity of less than 0.01% of the naturally occurring toxin counterpart.
- 24. (withdrawn): The immunogenic detoxified protein of claim 15, further comprising at least one CT subunit B.
- 25. (previously presented): The immunogenic detoxified protein of claim 19, further comprising at least one LT subunit B.